Last reviewed · How we verify

NCT06601452

Clinical Trial of Anovulatory Infertility

ENROLLING BY INVITATION EARLY_PHASE1 Last updated 11 February 2025
What this trial tests

EARLY_PHASE1 trial testing a compound prescription of Chinese medicine in Polycystic Ovary Syndrome in 650 participants. Enrolling by invitation.

Timeline
30 September 2024
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorAffiliated Hospital of Nanjing University of Chinese Medicine
PhaseEARLY_PHASE1
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment650
Start date30 September 2024
Primary completion31 December 2028
Estimated completion31 December 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Affiliated Hospital of Nanjing University of Chinese Medicine

Who can join

Adults 20 to 41, female only, with Polycystic Ovary Syndrome or Diminished Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to study the expression of clock genes and related proteins in follicular fluid and granulosa cells, depicting the periodic, amplitude, and phase changes of biological clock genes and related proteins in women of different ages during the reproductive period and in patients with ovulatory disorders. The study compares the periodicity, amplitude, and phase changes of Clock/Bmal1-TTFLs-klotho related proteins and genes in PCOS, DOR patients, and age-matched women with normal ovarian function, aiming to identify the key segments of ovarian clock gene period rhythm disorder under different disease states, and screen the key time points of clock gene oscillation abnormality. Omics analysis of the differences between groups, analysis of the relationship between gene transcription translation, protein expression, metabolites, and the expression of clock genes, and deduction of the dynamic changes and interaction relationships of the biological processes within the ovaries in regulating ovulatory disorders using the method of reinforcing the kidney and regulating the menstrual cycle. This aims to clarify that maintaining the ovarian biological clock period rhythm is an important biological basis for "the kidney dominating reproduction". The regulation mechanism of the treatment of ovulatory disorders using the method of reinforcing the kidney and regulating the menstrual cycle is explained from the perspective of the ovarian biological clock period rhythm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

Other Affiliated Hospital of Nanjing University of Chinese Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06601452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing